Shopping Cart 0
Cart Subtotal
AED 0

ASIA-PACIFIC ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 5505

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 8074

Details

MARKET OUTLOOK

Based on research conducted by Triton, the Asia-Pacific Alzheimer's therapeutics and diagnostics market is expected to rise at a CAGR of 8.14% over the forecast period of 2019-2027. India & China hold xx% of the world's population; this statistic indicates the medical infrastructure required to provide adequate services in these countries and also the ratio of patients per specialist.

The demand for diagnostic tests and personalized drug development for neurodegenerative diseases in countries like China, India, Japan, Australia & New Zealand, South Korea, ASEAN countries and rest of Asia-Pacific has risen considerably, which is proliferating the market growth in the region. However, the inadequacy of the government to fulfil the demand and the lack of trained specialists for Alzheimer's treatment are the prime factors limiting the growth in the region.

Recently, the governments in the Asia-Pacific region have taken multiple healthcare initiatives for providing cheaper drugs that are produced within their respective regions at low costs. However, e-selling of the drugs has been affected due to certain scams and illegal practices, resulting in a temporary ban on e-selling practices. The above-mentioned factors indicate a fair and progressive Alzheimer's disease market over the forecast period in the APAC region.

 

 

COMPETITIVE OUTLOOK

The top companies in the Alzheimer's disease market are GE Healthcare, Siemens Medical Solutions, Axon Neuroscience SE, Baxter International, Inc., Merck and Co., Pfizer, Inc., F. Hoffmann-La Roche AG, AbbVie, Inc., Sun Pharma and Biogen, Inc.

READ MORE

Table Of Content

Scope

TABLE OF CONTENTS

1. ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET-SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER'S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. INVESTMENTS OUTLOOK

2.8. KEY FINDINGS

2.9. INDUSTRY STRUCTURE

2.9.1. RESEARCH & DEVELOPMENT

2.9.2. MANUFACTURING

2.9.3. RAW MATERIALS

2.9.4. END-USER

2.9.5. WHOLESALERS

2.10. REGULATORY FRAMEWORK

2.11. ALZHEIMER'S DISEASE ETIOLOGY

2.12. PIPELINE OUTLOOK

2.13. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE

2.14. MARKET DRIVERS

2.14.1. GROWTH OF ALZHEIMER'S DISEASE

2.14.2. RISE IN GERIATRIC POPULATION

2.14.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.15. MARKET RESTRAINTS

2.15.1. STRINGENT GOVERNMENT REGULATIONS

2.15.2. HIGH TREATMENT COSTS OF ALZHEIMER'S DISEASE

2.16. MARKET OPPORTUNITIES

2.16.1. IN-VITRO DIAGNOSTIC TECHNIQUES IS A BOON TO THE MARKET

2.16.2. INCREASING R&D INVESTMENT IN PERSONALIZED MEDICINES

2.17. MARKET CHALLENGES

2.17.1. LESS AWARENESS CONCERNING NEW THERAPIES IN ALZHEIMER'S DISEASE

2.17.2. LACK OF SKILLED PROFESSIONALS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

3. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK-BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.2.3. PRODROMAL STAGE

3.1.3. THERAPEUTICS BY GENERIC AND BRANDED

3.1.3.1. BRANDED

3.1.3.2. GENERIC

3.2. DIAGNOSTICS

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-REGIONAL OUTLOOK

4.1. COUNTRY ANALYSIS

4.1.1. CHINA

4.1.2. INDIA

4.1.3. JAPAN

4.1.4. AUSTRALIA & NEW ZEALAND

4.1.5. SOUTH KOREA

4.1.6. ASEAN COUNTRIES

4.1.7. REST OF ASIA-PACIFIC

5. COMPETITIVE LANDSCAPE

5.1. ABBVIE, INC.

5.2. BAXTER INTERNATIONAL, INC.

5.3. BIOGEN, INC.

5.4. F. HOFFMANN-LA ROCHE AG

5.5. GE HEALTHCARE

5.6. MERCK AND, CO.

5.7. PFIZER, INC.

5.8. PIRAMAL ENTERPRISES, LTD.

5.9. SIEMENS MEDICAL SOLUTIONS

5.10. SUN PHARMA

6. METHODOLOGY AND SCOPE

6.1. RESEARCH SCOPE

6.2. SOURCES OF DATA

6.3. RESEARCH METHODOLOGY

 

 

 

 

TABLE LIST

TABLE 1 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO ALZHEIMER'S DISEASE

TABLE 3 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 4 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 6 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 7 ASIA-PACIFIC ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 8 ASIA-PACIFIC ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

 

 

 

 

 

FIGURE LIST

FIGURE 1 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 4 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 5 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 6 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 7 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 8 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 9 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 10 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 11 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 12 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 13 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 14 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 16 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 17 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 18 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 19 CHINA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 20 INDIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 21 JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 22 AUSTRALIA AND NEW ZEALAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 23 SOUTH KOREA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 24 ASEAN COUNTRIES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 25 REST OF ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027


List Of Figure

FIGURE LIST

FIGURE 1 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 4 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 5 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 6 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 7 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 8 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 9 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 10 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 11 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 12 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 13 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 14 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 16 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 17 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 18 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 19 CHINA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 20 INDIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 21 JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 22 AUSTRALIA AND NEW ZEALAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 23 SOUTH KOREA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 24 ASEAN COUNTRIES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 25 REST OF ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027


List Of Table

TABLE LIST

TABLE 1 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO ALZHEIMER'S DISEASE

TABLE 3 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 4 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 6 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 7 ASIA-PACIFIC ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 8 ASIA-PACIFIC ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

1. ABBVIE, INC.

2. BAXTER INTERNATIONAL, INC.

3. BIOGEN, INC.

4. F. HOFFMANN-LA ROCHE AG

5. GE HEALTHCARE

6. MERCK AND, CO.

7. PFIZER, INC.

8. PIRAMAL ENTERPRISES, LTD.

9. SIEMENS MEDICAL SOLUTIONS

10. SUN PHARMA

Company Profile

Company Profile Title

MARKET OUTLOOK

Based on research conducted by Triton, the Asia-Pacific Alzheimer's therapeutics and diagnostics market is expected to rise at a CAGR of 8.14% over the forecast period of 2019-2027. India & China hold xx% of the world's population; this statistic indicates the medical infrastructure required to provide adequate services in these countries and also the ratio of patients per specialist.

The demand for diagnostic tests and personalized drug development for neurodegenerative diseases in countries like China, India, Japan, Australia & New Zealand, South Korea, ASEAN countries and rest of Asia-Pacific has risen considerably, which is proliferating the market growth in the region. However, the inadequacy of the government to fulfil the demand and the lack of trained specialists for Alzheimer's treatment are the prime factors limiting the growth in the region.

Recently, the governments in the Asia-Pacific region have taken multiple healthcare initiatives for providing cheaper drugs that are produced within their respective regions at low costs. However, e-selling of the drugs has been affected due to certain scams and illegal practices, resulting in a temporary ban on e-selling practices. The above-mentioned factors indicate a fair and progressive Alzheimer's disease market over the forecast period in the APAC region.

 

 

COMPETITIVE OUTLOOK

The top companies in the Alzheimer's disease market are GE Healthcare, Siemens Medical Solutions, Axon Neuroscience SE, Baxter International, Inc., Merck and Co., Pfizer, Inc., F. Hoffmann-La Roche AG, AbbVie, Inc., Sun Pharma and Biogen, Inc.

READ MORE

Scope

TABLE OF CONTENTS

1. ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET-SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER'S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. INVESTMENTS OUTLOOK

2.8. KEY FINDINGS

2.9. INDUSTRY STRUCTURE

2.9.1. RESEARCH & DEVELOPMENT

2.9.2. MANUFACTURING

2.9.3. RAW MATERIALS

2.9.4. END-USER

2.9.5. WHOLESALERS

2.10. REGULATORY FRAMEWORK

2.11. ALZHEIMER'S DISEASE ETIOLOGY

2.12. PIPELINE OUTLOOK

2.13. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE

2.14. MARKET DRIVERS

2.14.1. GROWTH OF ALZHEIMER'S DISEASE

2.14.2. RISE IN GERIATRIC POPULATION

2.14.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.15. MARKET RESTRAINTS

2.15.1. STRINGENT GOVERNMENT REGULATIONS

2.15.2. HIGH TREATMENT COSTS OF ALZHEIMER'S DISEASE

2.16. MARKET OPPORTUNITIES

2.16.1. IN-VITRO DIAGNOSTIC TECHNIQUES IS A BOON TO THE MARKET

2.16.2. INCREASING R&D INVESTMENT IN PERSONALIZED MEDICINES

2.17. MARKET CHALLENGES

2.17.1. LESS AWARENESS CONCERNING NEW THERAPIES IN ALZHEIMER'S DISEASE

2.17.2. LACK OF SKILLED PROFESSIONALS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

3. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK-BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.2.3. PRODROMAL STAGE

3.1.3. THERAPEUTICS BY GENERIC AND BRANDED

3.1.3.1. BRANDED

3.1.3.2. GENERIC

3.2. DIAGNOSTICS

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-REGIONAL OUTLOOK

4.1. COUNTRY ANALYSIS

4.1.1. CHINA

4.1.2. INDIA

4.1.3. JAPAN

4.1.4. AUSTRALIA & NEW ZEALAND

4.1.5. SOUTH KOREA

4.1.6. ASEAN COUNTRIES

4.1.7. REST OF ASIA-PACIFIC

5. COMPETITIVE LANDSCAPE

5.1. ABBVIE, INC.

5.2. BAXTER INTERNATIONAL, INC.

5.3. BIOGEN, INC.

5.4. F. HOFFMANN-LA ROCHE AG

5.5. GE HEALTHCARE

5.6. MERCK AND, CO.

5.7. PFIZER, INC.

5.8. PIRAMAL ENTERPRISES, LTD.

5.9. SIEMENS MEDICAL SOLUTIONS

5.10. SUN PHARMA

6. METHODOLOGY AND SCOPE

6.1. RESEARCH SCOPE

6.2. SOURCES OF DATA

6.3. RESEARCH METHODOLOGY

 

 

 

 

TABLE LIST

TABLE 1 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO ALZHEIMER'S DISEASE

TABLE 3 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 4 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 6 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 7 ASIA-PACIFIC ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 8 ASIA-PACIFIC ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

 

 

 

 

 

FIGURE LIST

FIGURE 1 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 4 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 5 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 6 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 7 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 8 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 9 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 10 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 11 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 12 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 13 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 14 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 16 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 17 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 18 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 19 CHINA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 20 INDIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 21 JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 22 AUSTRALIA AND NEW ZEALAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 23 SOUTH KOREA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 24 ASEAN COUNTRIES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 25 REST OF ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027


List Of Figure

FIGURE LIST

FIGURE 1 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 3 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 4 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 5 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 6 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 7 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 8 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 9 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 10 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 11 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 12 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 13 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 14 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 15 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 16 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 17 ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 18 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 19 CHINA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 20 INDIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 21 JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 22 AUSTRALIA AND NEW ZEALAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 23 SOUTH KOREA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 24 ASEAN COUNTRIES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027

FIGURE 25 REST OF ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET 2019-2027


List Of Table

TABLE LIST

TABLE 1 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO ALZHEIMER'S DISEASE

TABLE 3 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 4 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 6 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 7 ASIA-PACIFIC ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 8 ASIA-PACIFIC ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTIC MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

1. ABBVIE, INC.

2. BAXTER INTERNATIONAL, INC.

3. BIOGEN, INC.

4. F. HOFFMANN-LA ROCHE AG

5. GE HEALTHCARE

6. MERCK AND, CO.

7. PFIZER, INC.

8. PIRAMAL ENTERPRISES, LTD.

9. SIEMENS MEDICAL SOLUTIONS

10. SUN PHARMA